KR20220031995A - 항체 표적화된 식균작용을 통해 질환 유발 인자를 고갈시키는 방법 - Google Patents

항체 표적화된 식균작용을 통해 질환 유발 인자를 고갈시키는 방법 Download PDF

Info

Publication number
KR20220031995A
KR20220031995A KR1020217036237A KR20217036237A KR20220031995A KR 20220031995 A KR20220031995 A KR 20220031995A KR 1020217036237 A KR1020217036237 A KR 1020217036237A KR 20217036237 A KR20217036237 A KR 20217036237A KR 20220031995 A KR20220031995 A KR 20220031995A
Authority
KR
South Korea
Prior art keywords
dectin
antibody
cells
phagocytosis
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217036237A
Other languages
English (en)
Korean (ko)
Inventor
파나지오티스 포타키스
찬티 마리아테기 찬
루오 시 시
아담 루이스 살레스
네나드 토마세빅
Original Assignee
드렌 바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 드렌 바이오, 인크. filed Critical 드렌 바이오, 인크.
Publication of KR20220031995A publication Critical patent/KR20220031995A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020217036237A 2019-04-05 2020-04-03 항체 표적화된 식균작용을 통해 질환 유발 인자를 고갈시키는 방법 Ceased KR20220031995A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962830139P 2019-04-05 2019-04-05
US62/830,139 2019-04-05
PCT/US2020/026721 WO2020206354A1 (en) 2019-04-05 2020-04-03 Methods of depleting disease causing agents via antibody targeted phagocytosis

Publications (1)

Publication Number Publication Date
KR20220031995A true KR20220031995A (ko) 2022-03-15

Family

ID=72667025

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217036237A Ceased KR20220031995A (ko) 2019-04-05 2020-04-03 항체 표적화된 식균작용을 통해 질환 유발 인자를 고갈시키는 방법

Country Status (12)

Country Link
US (2) US20220169737A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947467A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022527646A (cg-RX-API-DMAC7.html)
KR (1) KR20220031995A (cg-RX-API-DMAC7.html)
CN (1) CN114502585A (cg-RX-API-DMAC7.html)
AU (1) AU2020253621A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019950A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136272A1 (cg-RX-API-DMAC7.html)
IL (1) IL286967A (cg-RX-API-DMAC7.html)
MX (1) MX2021012035A (cg-RX-API-DMAC7.html)
SG (1) SG11202110663UA (cg-RX-API-DMAC7.html)
WO (1) WO2020206354A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
IL297782A (en) 2020-05-01 2022-12-01 Bolt Biotherapeutics Inc Anti-dectin-2 antibodies
EP4225373A4 (en) 2020-10-07 2025-01-08 Dren Bio, Inc. ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF
KR20240170833A (ko) * 2022-04-04 2024-12-04 드렌 바이오, 인크. 덱틴-1 및 cd20에 결합하는 다중특이성 결합 단백질 및 이의 사용 방법
KR20250006353A (ko) * 2022-04-04 2025-01-10 드렌 바이오, 인크. 항-덱틴-1 항체 및 이의 사용 방법
AU2024316588A1 (en) * 2023-07-31 2026-01-29 Dren Bio Management, Inc. Multispecific binding proteins that bind dectin-1 and trop-2 and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI423985B (zh) * 2007-02-23 2014-01-21 貝勒研究協會 利用dectin-1活化人類抗原呈現細胞之醫療應用
US20120244155A1 (en) * 2011-03-22 2012-09-27 Baylor Research Institute Dendritic Cells (DCs) Targeting for Tuberculosis (TB) Vaccine
WO2018176159A1 (en) * 2017-03-31 2018-10-04 Zymeworks Inc. Tumor antigen presentation inducer constructs and uses thereof
TW201904588A (zh) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
CN112567026B (zh) * 2018-07-19 2024-08-23 昂科霍斯特公司 Il-31改善用于癌症的基于巨噬细胞的过继性细胞疗法的功效
SG11202100555PA (en) * 2018-07-27 2021-02-25 Alector Llc Anti-siglec-5 antibodies and methods of use thereof

Also Published As

Publication number Publication date
US20250206826A1 (en) 2025-06-26
US20220169737A1 (en) 2022-06-02
CA3136272A1 (en) 2020-10-08
EP3947467A1 (en) 2022-02-09
IL286967A (en) 2021-12-01
BR112021019950A2 (pt) 2021-12-07
JP2022527646A (ja) 2022-06-02
AU2020253621A1 (en) 2021-11-11
SG11202110663UA (en) 2021-10-28
EP3947467A4 (en) 2023-01-04
CN114502585A (zh) 2022-05-13
MX2021012035A (es) 2022-03-11
WO2020206354A1 (en) 2020-10-08
JP2025096316A (ja) 2025-06-26

Similar Documents

Publication Publication Date Title
US20250206826A1 (en) Methods of depleting disease causing agents via antibody targeted phagocytosis
JP7803942B2 (ja) 抗デクチン-1抗体及びその使用方法
EP3227333B1 (en) Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseases
US8758749B2 (en) Biological materials and uses thereof
KR20200104299A (ko) 항 lag-3 항체 및 이의 용도
JP2025511389A (ja) デクチン-1及びcd20に結合する多重特異性結合タンパク質ならびにその使用方法
JP2022525937A (ja) Btn2に対する特異性を有する抗体及びその使用
US20220229059A1 (en) Tumor cell-derived exosomes and their applications
HK40102072A (en) Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseases
CN116724054A (zh) 抗Dectin-1抗体和其使用方法
EA052891B1 (ru) Полиспецифические связывающие белки, которые связывают дектин-1 и cd20, и способы их применения
HK40009518A (en) Anti-lag-3 antibody and the use thereof
HK40009518B (en) Anti-lag-3 antibody and the use thereof
EP3856776A1 (en) Antigen-binding fragment and/or aptamer for binding to an extracellular part of cd9 and therapeutic uses
HK1244491B (en) Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601